In synthetic peptide chemistry, maleimidopropionic acid (MPA) serves as the covalent bioconjugation linker in CJC-1295 with DAC, differentiating long-acting constructs from short-acting GHRH analogs like CJC-1295 No DAC. This technical comparative analysis evaluates the structural chemistry, receptor dynamics, and distinct pathways of CJC-1295 No DAC and Kisspeptin-10 for laboratory research applications.
In synthetic peptide chemistry, maleimidopropionic acid (MPA) serves as the covalent bioconjugation linker in CJC-1295 with DAC, differentiating long-acting constructs from short-acting GHRH analogs like CJC-1295 No DAC. This technical comparative analysis evaluates the structural chemistry, receptor dynamics, and distinct pathways of CJC-1295 No DAC and Kisspeptin-10 for laboratory research applications.
In peptide synthesis, maleimidopropionic acid (MPA) is a bi-functional chemical linker utilized to achieve covalent conjugation with serum proteins. When incorporated at the Lys30 residue of modified growth hormone-releasing hormone (GRF 1-29), maleimidopropionic acid CJC-1295 forms what is commercially designated as CJC-1295 with DAC (Drug Affinity Complex). Once administered in animal models, the maleimide functional group selectively reacts with the free thiol group on Cys34 of circulating serum albumin. This irreversible covalent bond protects the peptide backbone from rapid enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV) and renal filtration, dramatically extending plasma half-life from approximately 30 minutes to over 6–8 days.
Conversely, CJC-1295 No DAC—frequently referenced in literature as Modified GRF 1-29—omits the maleimidopropionic acid linker completely. Without the MPA moiety, CJC-1295 No DAC retains a shortened half-life (~30 minutes in rodent models), preserving the physiological, pulsatile release pattern of growth hormone (GH) without causing prolonged continuous receptor activation. Researchers selecting between these variants prioritize whether continuous baseline elevation or natural pulsatile dynamics are required for their specific in vitro or preclinical protocol.
CJC-1295 No DAC is a 29-amino-acid synthetic peptide analog derived from human growth hormone-releasing hormone (GHRH 1-44). Four specific amino acid substitutions (Tyr1 to D-Ala1, Gln8 to Ala8, Gly15 to Ala15, and Leu27 to Lys27) are incorporated into its sequence to enhance structural stability and resistance against DPP-IV enzymatic degradation compared to native GHRH.
Preclinical research demonstrates that CJC-1295 No DAC binds directly to the GHRH receptor (GHRHR) on anterior pituitary somatotropes. Receptor binding activates the intracellular G-protein-coupled receptor (GPCR) pathway, triggering adenylyl cyclase to increase cyclic adenosine monophosphate (cAMP) levels and activate protein kinase A (PKA). This signal transduction cascade stimulates the synthesis and pulsatile secretion of endogenous growth hormone. Consequently, hepatic production of insulin-like growth factor 1 (IGF-1) is elevated. In cellular and animal models, this axis is studied extensively for its role in cellular proliferation, nitrogen retention, lipid metabolism, and tissue repair.
While CJC-1295 variants target the somatotropic axis via GHRHR, Kisspeptin-10 functions via an entirely distinct endocrine pathway. Kisspeptin-10 is an endogenous 10-amino-acid decapeptide cleaved from the larger prepro-kisspeptin precursor protein (encoded by the KISS1 gene). It acts as the primary endogenous agonist for the G-protein-coupled receptor KISS1R (formerly known as GPR54), expressed predominantly in the arcuate nucleus and anteroventral periventricular nucleus of the hypothalamus.
In vitro and animal models indicate that Kisspeptin-10 binding to KISS1R activates the Gq/11-phospholipase C (PLC) signaling cascade, generating intracellular inositol trisphosphate (IP3) and diacylglycerol (DAG). This induces intracellular calcium mobilization and protein kinase C (PKC) activation, driving the release of Gonadotropin-Releasing Hormone (GnRH) into the hypophyseal portal system. The downstream effect of Kisspeptin-10 in preclinical models is the robust secretion of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) from pituitary gonadotropes, making it a pivotal reagent for researching reproductive endocrinology, pubertal onset, and steroidogenesis.
Evaluating CJC-1295 No DAC against Kisspeptin-10 highlights fundamental differences in receptor specificity, downstream signaling pathways, and physiological endpoints. CJC-1295 No DAC specifically regulates somatotropic activity through GHRHR activation, elevating GH and IGF-1 for tissue turnover, extracellular matrix remodelling, and metabolic research. In contrast, Kisspeptin-10 operates exclusively upstream in the Hypothalamic-Pituitary-Gonadal (HPG) axis, governing GnRH secretion and gonadotropin output.
In multi-pathway endocrine investigations, researchers often evaluate complementary peptides across these distinct axes. For example, growth hormone secretagogues like Ipamorelin or Sermorelin are studied alongside CJC-1295 No DAC to assess synergistic GHRHR/GHSR stimulation, whereas compounds targeting gonadotropic control are compared directly to Kisspeptin-10. Detailed protocol comparisons and receptor affinity matrices are detailed further in our preclinical research library.
The presence or absence of the maleimidopropionic acid linker fundamentally transforms peptide kinetics. When maleimidopropionic acid CJC-1295 is introduced into serum-containing media or live animal assays, its rapid conjugation to albumin prevents enzymatic degradation, extending its half-life to several days. This allows continuous activation of the GHRHR, resulting in elevated baseline GH and IGF-1 levels without distinct episodic peaks.
Conversely, CJC-1295 No DAC and Kisspeptin-10 exhibit rapid clearance kinetics. CJC-1295 No DAC exhibits an elimination half-life of 30 to 40 minutes in vivo, mimicking natural pulsatile somatotrope activity. Kisspeptin-10 displays an even shorter half-life (under 10 minutes in circulating models) due to rapid endopeptidase cleavage. Consequently, researchers investigating acute signaling events or pulsatile release dynamics select CJC-1295 No DAC or Kisspeptin-10 over albumin-bound conjugates.
Accurate analytical results in laboratory experiments depend directly on peptide purity, sequence fidelity, and freedom from biological contaminants. PX1 Research implements rigorous quality control standards across every production lot of synthetic peptides manufactured in our USA facilities.
Each batch of CJC-1295 No DAC and Kisspeptin-10 undergoes dual-stage analytical verification. Purity is validated via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a minimum purity threshold of 99.0%. Molecular mass is confirmed using Electrospray Ionization Mass Spectrometry (ESI-MS) to guarantee accurate sequence assembly without truncations or deletion sequences. Furthermore, every lot is subjected to Chromogenic Recombinant Factor C (rFC) testing to confirm endotoxin levels remain strictly below <0.5 EU/mg, preventing cell culture toxicity or off-target immune responses.
Lyophilized research peptides must be handled under strict sterile conditions to preserve chemical integrity and prevent bacterial contamination. Reconstitution protocols should utilize sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) or sterile research-grade phosphate-buffered saline (PBS, pH 7.4), depending on the experimental model.
To reconstitute, slowly direct the diluent down the glass wall of the vial without agitating the lyophilized cake. Allow the cake to dissolve fully via gentle rotation rather than vigorous shaking, which can cause peptide shear stress and aggregation. Once reconstituted, stock solutions should be aliquoted into single-use polypropylene microtubes to avoid repeated freeze-thaw cycles. Stored at -20°C or -80°C, reconstituted aliquots maintain chemical stability for extended laboratory trial periods.
PX1 Research provides fully verified research reagents tailored to academic institutions, biotechnology organizations, and analytical laboratories. All inventory is manufactured in compliance with ISO 9706/GMP guidelines and shipped directly from our primary distribution hubs in California and Arizona.
Every shipped product includes a lot-specific Certificate of Analysis (COA) containing raw RP-HPLC chromatograms, ESI-MS spectra, and quantitative endotoxin test reports. Orders placed before 1:00 PM PST Monday through Friday qualify for same-day dispatch. For institutional bulk procurement, laboratory managers may establish a dedicated bulk research account to access volume pricing and lot-reservation services. Explore our full catalog of high-purity peptides via the all-peptides directory.
What is the function of maleimidoproprionic acid in CJC-1295?
Maleimidopropionic acid (MPA) acts as a bioconjugation linker in CJC-1295 with DAC. It covalently binds to the Cys34 residue of circulating serum albumin, protecting the peptide from enzymatic breakdown and extending its half-life in laboratory models from minutes to several days.
What is the key structural difference between CJC-1295 No DAC and CJC-1295 with DAC?
CJC-1295 No DAC (Modified GRF 1-29) lacks the maleimidopropionic acid linker present in CJC-1295 with DAC. Consequently, CJC-1295 No DAC has a short half-life (~30 minutes) and induces pulsatile GH release, whereas the DAC variant provides prolonged, baseline GH elevation.
How does CJC-1295 No DAC differ in mechanism from Kisspeptin-10?
CJC-1295 No DAC targets the GHRH receptor on pituitary somatotropes to stimulate growth hormone release. Kisspeptin-10 binds to the KISS1R receptor in the hypothalamus to stimulate GnRH secretion, controlling the gonadotropic (LH/FSH) axis.
What purity levels are verified for PX1 CJC-1295 No DAC and Kisspeptin-10?
Every lot of CJC-1295 No DAC and Kisspeptin-10 from PX1 Research is verified by RP-HPLC and ESI-MS to achieve ≥99.0% chemical purity with endotoxin levels certified under <0.5 EU/mg.
Which diluent should be used for reconstituting CJC-1295 No DAC for laboratory storage?
Reconstitution is recommended using sterile Bacteriostatic Water (0.9% benzyl alcohol) for multi-dose laboratory sampling or sterile PBS (pH 7.4) for immediate cell culture assays.
How should reconstituted peptide stock solutions be stored to prevent degradation?
Reconstituted solutions should be divided into single-use aliquots to prevent freeze-thaw degradation and stored at -20°C or -80°C in airtight microcentrifuge tubes.
What animal models are used to study Kisspeptin-10?
Kisspeptin-10 is widely studied in rodent and non-human primate models to evaluate pubertal development, GnRH neuronal firing, LH surge dynamics, and reproductive endocrinology pathways.
Does Kisspeptin-10 affect growth hormone or IGF-1 levels in research models?
Preclinical data indicate that Kisspeptin-10 selectively activates the KISS1R/GnRH axis and does not directly bind to GHRHR or alter GH and IGF-1 levels.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research compounds are manufactured in USA-based cGMP-compliant facilities and shipped directly from dispatch centers located in California and Arizona.
Can laboratories obtain lot-specific COAs prior to compound evaluation?
Yes, PX1 Research provides downloadable, lot-specific Certificates of Analysis featuring full RP-HPLC and mass spectrometry data directly on product pages or upon request.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.